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Introduction
Ginseng and sanqi (the roots of Panax ginseng and Panax 
notoginseng), 2 well-known traditional Chinese medicinal 
herbs, have been greatly used in several Asian countries for 
thousands of years[1].  Despite certain distinct remedial us-
ages, comparable therapeutic effects, such as the promotion 
of blood circulation, have been reported for these 2 herbs. 
Both ginseng and sanqi are commonly used for the treatment 
of coronary heart disease and cerebral vascular disease[2–4]. 
Belonging to the same genus, ginseng and sanqi possess 
similar constituents, including their unique active ingredi-
ents, ginsenosides[5,6].  Cumulated research outcomes have 
indicated that identical and variable ginsenosides in these 2 
herbs are possibly responsible for the comparable and dis-
tinct therapeutic effects between ginseng and sanqi[7].
Ginsenosides are triterpene saponins that have a common 
4 ring hydrophobic steroid-like structure with sugar moieties 
attached mostly at the C-3, C-6, or C-20 position[8].  So far, 
more than 80 ginsenosides have been isolated from over 10 
Panax taxa, and most of these are derived from 4 types of 
aglycones: protopanaxadiol, protopanaxatriol, oleanolic acid, 
and ocotillol[9].  Biological activities, such as neuroprotective 
effects, antitumoral activity, and cardiac therapeutic effects 
have been documented for these ginsenosides[1,7,10].  The 
different sugar moieties in ginsenosides are assumed to pro-
vide specificity for the diverse therapeutic effects of variable 
ginsenosides.  Although the cardiac therapeutic effects of 
ginsenosides have been documented, the detailed molecular 
mechanism triggering this medicinal role is still unknown. 
It has been speculated that calcium channel blocking or the 
antifree-radical action of ginsenosides may be responsible for 
their cardiac therapeutic effect[11].  
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Cardiac glycosides, such as ouabain and digoxin, also 
contain a core steroid-like structure and have been utilized 
for the treatment of congestive heart failure[12].  The cardiac 
therapeutic effect of cardiac glycosides is a result of their 
reversible inhibition on the α-subunit of the membrane-
bound Na+/K+-ATPase, mainly, but not exclusively, located 
in the human myocardium[13].  This inhibition leads to the 
accumulation of sodium in cardiac cells, which are enforced 
to promote the sodium-calcium exchange system in the cell 
membrane, thus causing a higher level of intracellular and 
myocardial calcium.  The elevated intracellular calcium in-
duces positive inotropy that eventually accentuates the force 
of myocardial contraction.
In light of the structural similarity between ginsenosides 
and cardiac glycosides, as well as their consentaneous utiliza-
tion in cardiac therapy, we determined whether ginsenosides 
of certain sugar attachments may act as active ingredients 
responsible for the cardiac therapeutic effects of ginseng and 
sanqi via the same molecular mechanism triggered by cardiac 
glycosides.  In this study, the inhibitory potency of various 
ginsenosides and ouabain on Na+/K+-ATPase was examined 
and compared.  The molecular modeling and docking of rep-
resentative ginsenosides to Na+/K+-ATPase were exhibited 
to reveal the observed difference in Na+/K+-ATPase inhibi-
tion among ginsenosides at the molecular level.
Materials and methods
Chemicals and reagents  Ginsenosides Rb1, Rb2, Rb3, 
Rc, Rd, Rg3, Rh2, PPD, Re, Rf, Rg2, Rg1, Rh1, and PPT, as 
well as pseudoginsenoside F11, were purchased from Scien-
tific Pharmaceutical Elite Company (Taiwan).  Ginsenoside 
R1 was obtained from ChromaDex (Irvine, CA, USA). 
Oleanolic acid and ouabain were obtained from Sigma (St 
Louis, MO, USA).  The phosphate assay kit was purchased 
from Amresco (Solon, Ohio, USA).
Measurement of Na+/K+-ATPase activity  The Na+/K+-
ATPase activity was determined by measuring the amount of 
inorganic phosphate (Pi) liberated from ATP[14].  A commer-
cial Na+/K+-ATPase from the porcine cerebral cortex (Sigma, 
USA; 0.3 units/mg) was incorporated into a 1 mL reaction 
mixture containing 3 mmol/L ATP, 5 mmol/L MgCl2, 80 
mmol/L NaCl, 20 mmol/L KCl, and 40 mmol/L Tris-HCl 
(pH 7.8).  The enzymatic reaction was terminated by adding 
250 µL of 30% (w/v) trichloroacetic acid after the incuba-
tion period.  After centrifugation at 10 000×g for 10 min, 
the supernatant was diluted 12.5-fold with deionized water 
and then 50 µL color development reagent, which was pro-
vided by the phosphate assay kit, was added.  After 30 min 
of incubation at room temperature, the color intensity was 
measured at 620 nm on a SpectraMax M2 reader (Molecular 
Devices, Sunnyvale, CA, USA).  Sodium pump activity was 
expressed as µmol Pi liberated from ATP by 1 mg of Na+/K+-
ATPase in 1 h.  
Data analysis  Data were expressed as mean±SEM of 5 
replicates, and one-way ANOVA was performed on SPSS 
12.0 for Windows (SPSS, Chicago, IL, USA).  Differences 
were considered statistically significant at P<0.05.  
Molecular modeling and docking  The crystal structure 
of pig renal Na+/K+-ATPase (Protein Data Bank [PDB] code 
3B8E) was downloaded from the PDB[15].  In order to facili-
tate the docking process, we removed the β and γ subunits of 
the Na+/K+-ATPase, as well as the water molecules and coun-
ter ions surrounding the remaining α subunit.  The modified 
Na+/K+-ATPase after hydrogen saturation was minimized 
with the CHARMm force field[16] using the Discover Stu-
dio 2.0 package (http://accelrys.com/products/discovery-
studio).  The 2-D structures of ginsenosides used in this 
study were constructed by using the ChemDraw program, 
and their corresponding 3-D structures were converted by 
the Chem3D program (http://www.cambridgesoft.com). 
All of the ginsenosides were either 20(S)-protopanaxadiol or 
20(S)-protopanaxatriol.  The pocket for binding cardiac gly-
cosides in the Na+/K+-ATPase α subunit was defined among 
the extracellular loops linking transmembrane segments as 
reported by Qiu et al[17,18], and the subunit-binding domain 
was defined as the region of the sphere with a 10 Å radius 
from the center of the binding pocket, which lies between 
I315 and L793 of the modified Na+/K+-ATPase.  Docking 
of the ginsenosides was performed in silico by employing 
the LibDock module[19] in the Discover Studio 2.0 package. 
There were 100 hotspots identified in the binding pocket. 
The LibDock methodology effectively executed the docking 
of combinatorial libraries of compounds in a high-through-
put manner while keeping the protein structure fixed[20]. 
With the energy threshold set as 20 kcal/mol, 76 conforma-
tions of Rg3, 118 conformations of Rh2, 26 conformations 
of PPD, and 25 conformations of PPT were generated for 
docking, respectively.  The ginsenoside-Na+/K+-ATPase 
complexes were evaluated by LibDockscore[21].  This scor-
ing resembles piecewise linear potential[22] by summing over 
interacting atoms in the specific ginsenoside-Na+/K+-ATPase 
complexes.  
Results
Structural comparison between ginsenosides and 
ouabain  Similar to cardiac glycosides, such as ouabain, 
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ginsenosides comprise a core steroid-like structure with 
sugars and other functional groups attached at variable posi-
tions (Figure 1).  Protopanaxadiol ginsenosides, 1 of the 2 
major ginsenoside groups, possess sugar moieties at the C-3 
and C-20 positions, while protopanaxatriol ginsenosides, 
the other major group, possess a hydroxyl group at the C-3 
position and sugar moieties at the C-6 and C-20 positions 
of the steroid-like structure.  Among the 3 sugar attachment 
positions in ginsenosides, the C-3 position of the steroid-like 
structure is equivalent to the unique sugar attachment posi-
tion of cardiac glycosides.  
Inhibition of porcine Na+/K+-ATPase by ginsenosides 
To verify whether ginsenosides and their aglycones exhibit a 
similar therapeutic effect via the same mechanism triggered 
by ouabain, that is, accentuating the force of myocardial 
contraction by elevating calcium concentration via the in-
hibition of Na+/K+-ATPase, a commercial Na+/K+-ATPase 
from the porcine cerebral cortex was used to evaluate the 
inhibitory potency of 7 protopanaxadiol ginsenosides and 
their aglycone PPD, 6 protopanaxatriol ginsenosides and 
their aglycone PPT, pseudoginsenoside F11, oleanolic acid, 
and ouabain.  Among the protopanaxadiol ginsenosides, 
Rg3, Rh2, and PPD, which contain no sugar moieties at the 
C-20 position of the steroid-like structure, showed signifi-
Figure 1.  Chemical structures of 7 protopanaxadiol ginsenosides and their aglycone PPD, 6 protopanaxatriol ginsenosides and their aglycone PPT, 
pseudoginsenoside F11, oleanolic acid, and ouabain.
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cant inhibition on Na+/K+-ATPase activity, regardless of the 
sugar attachment at the C-3 position; however, the inhibitory 
potency was mostly reduced (for ginsenoside Rd) or com-
pletely abolished (for ginsenosides, Rb1, Rb2, Rb3, and Rc) 
when monosaccharide or disaccharide was attached to the 
C-20 position (Figure 2A).  All of the 6 protopanaxatriol gin-
senosides (Re, R1, Rf, Rg1, Rg2, and Rh1) containing sugar 
moieties at the C-6 position of the steroid-like structure did 
not inhibit Na+/K+-ATPase, while PPT, which does not con-
tain sugar moieties at the C-6 and C-20 positions, possessed 
considerable inhibitory potency (Figure 2B).  Similar to pro-
topanaxatriol ginsenosides, pseudoginsenoside F11, which 
contains a disaccharide attached at the C-6 position, did not 
inhibit Na+/K+-ATPase, while oleanolic acid, which does 
not contain sugar, possessed significant inhibitory potency 
(Figure 2C).  Under our experimental conditions, the inhibi-
tory potency of all ginsenosides on porcine Na+/K+-ATPase 
was evidently lower than that of ouabain; the IC50 of ouabain 
(0.45 µmol/L) was approximately 120 times lower than that 
of ginsenoside Rh2 (55 µmol/L), the strongest inhibitor of 
Na+/K+-ATPase among the ginsenosides examined in this 
study (Figure 3).
Molecular modeling and docking of ginsenosides to 
Na+/K+-ATPase  To reveal the observed difference in Na+/
K+-ATPase inhibition among ginsenosides at the molecular 
level, representative ginsenosides, Rg2, Rg3, Rd, Rb1, PPD, 
PPT, and Rh1 were subjected to molecular modeling and 
docking to the extracellular domain of the α subunit of Na+/
K+-ATPase.  In accordance with the results of the Na+/K+-
ATPase inhibitory assay for these representative ginseno-
sides, only PPD, Rh2, and Rg3, which contained 0, 1, and 2 
sugar units at the C-3 position, but no sugar attached at the 
C-6 and C-20 positions, could dock into the extracellular 
pocket of the Na+/K+-ATPase α subunit (Figure 4).  The core 
steroid-like structure of PPD, Rh2, or Rg3 was trapped in a 
cave (shown in green with dimensional limitations of 10.5 
and 9.2 Å for the top and bottom areas, respectively) of the 
extracellular pocket.  The protrusive alkyl side chain attached 
at the C-20 position of the steroid-like structure was located 
in a narrow space deeper than the cave.  In comparison with 
PPD, the extra monosaccharide and disaccharide of Rh2 and 
Figure 2.  Inhibition of porcine Na+/K+-ATPase by ginsenosides. 
Inhibitory potency of (A) 7 protopanaxadiol ginsenosides and their 
aglycone PPD, (B) 6 protopanaxatriol ginsenosides and their aglycone 
PPT, and (C) pseudoginsenoside F11 (PF11), oleanolic acid (OA), 
and ouabain (OUA) were observed as the reduction of Pi liberation 
released from ATP by a constant amount of commercial porcine Na+/
K+-ATPase.  Data represent mean±SEM of 5 replicates.  bP<0.05, 
cP<0.01 vs control group (CON; deionized water only).
Figure 3.  Inhibitory potency of ouabain and ginsenoside Rh2 on 
porcine Na+/K+-ATPase.  Inhibitory potency of various concentrations 
of ouabain and ginsenoside Rh2 was observed as the reduction of Pi 
liberation released from ATP by a constant amount of commercial 
porcine Na+/K+-ATPase.
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Rg3 at the C-3 position of the steroid-like structure were 
located outside of the cave and were freely exposed to the 
extracellular space.
Detailed molecular interactions between Rg3, Rh2, PPD, 
or PPT and the extracellular pocket of Na+/K+-ATPase are 
shown in Figure 5.  Three hydrogen bonds were found be-
tween the sugar moieties at the C-3 position of Rg3 or Rh2 
and Na+/K+-ATPase (Figure 5A, 5B).  Among these hydro-
gen bond interactions, R880 of Na+/K+-ATPase was involved 
in 2 hydrogen bonds with the sugar moieties at the C-3 
position of Rh2.  Presumably, the interaction between the 
sugar moieties at the C-3 position of ginsenosides was ben-
eficial for their binding to the extracellular pocket of Na+/
K+-ATPase.  Only 1 hydrogen bond was observed between 
the hydroxyl group at the C-20 position of PPD and V798 of 
Na+/K+-ATPase (Figure 5C).  Two hydrogen bonds were ob-
served between PPT and Na+/K+-ATPase; one was between 
the hydroxyl group at the C-3 position of PPT and N790 of 
Figure 4.  Modeling of ginsenosides binding to the extracellular pocket of the Na+/K+-ATPase α subunit.  (A) core steroid-like structure of 
ginsenoside Rg3 was trapped in a cave (shown in green with dimensional limitations of 10.5 and 9.2 Å for the top and bottom areas, respectively) of 
the extracellular pocket of the Na+/K+-ATPase α subunit. Similar structural interaction was observed for ginsenoside Rh2 (Rg3 without the orange 
glucose molecule) and PPD (Rg3 without the orange and pink glucose molecules).  (B) molecular interaction between ginsenoside Rg3 and the 
extracellular binding pocket of the Na+/K+-ATPase α subunit.  Ginsenoside Rg3 and the binding pocket of Na+/K+-ATPase were displayed in ball-
and-stick and space-fill modes, respectively.  Left-side view (C) of the extracellular space facing the binding pocket of Na+/K+-ATPase (B). 
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Na+/K+-ATPase, and the other between the hydroxyl group 
at the C-12 position of PPT and R904 of Na+/K+-ATPase 
(Figure 5D).  Our observation of hydrogen bond interac-
tions between Arg and ginsenosides was in accordance with 
that between Arg in the H7–H8 loop of human Na+/K+-
ATPase and cardiac glycosides[23].  The interaction between 
ginsenosides and the extracellular pocket of Na+/K+-ATPase 
putatively blocked the entrance of ions rather than impeded 
the active site of Na+/K+-ATPase located in the intracellular 
region.  LibDockscores of the Rg3, Rh2, PPD, and PPT were 
145.069, 148.118, 100.344, and 103.058, respectively.  The 
docking score results were consistent with the observations 
in the inhibitory assay.
To rationalize the steric hindrance of sugar attachment 
at the C-6 or C-20 position of the steroid-like structure, the 
molecular fitness of PPD, PPT, and Rh1 or Rg3, Rd, and 
Rb1 in the cave of the extracellular pocket of the Na+/K+-
ATPase α subunit was depicted and compared (Figure 6). 
The altered dimension of ginsenoside increased from 6.1 
Å (PPD) to 7.1 Å (PPT) or 11.8 Å (Rh1) when a hydroxyl 
group or glucose was attached to the C-6 position of the 
steroid-like structure (Figure 6, left).  Since the dimensional 
Figure 5.  Detailed molecular interactions between the extracellular pocket of Na+/K+-ATPase and (A) Rg3, (B) Rh2, (C) PPD, and (D) PPT. 
Amino acid residues of Na+/K+-ATPase close to ginsenosides are shown in the wire frame, and the structures of ginsenosides are shown in the 
scaled ball and stick. Green dashed lines represent the hydrogen bonds between ginsenosides and Na+/K+-ATPase.  Amino acids involved in 
hydrogen bonding to ginsenosides are in green.
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limitations of the extracellular cave of the Na+/K+-ATPase 
α subunit were 10.5 and 9.2 Å, both PPD and PPT, but not 
Rh1, could fit in the cave.  Therefore, PPD and PPT, but not 
Rh1, possessed inhibitory potency on Na+/K+-ATPase.  The 
altered dimension of ginsenoside increased from 3.1 Å (Rg3) 
to 9.6 Å (Rd) or 14.6 Å (Rb1) when monosaccharide or di-
saccharide was attached to the C-20 position of the steroid-
like structure (Figure 6, right).  Consequently, Rg3, but not 
Rb1, could fit in the cave and possessed inhibitory potency 
on Na+/K+-ATPase.  Rd (9.6 Å) could pass through the top 
(10.5 Å), but could not reach the bottom (9.2 Å) of the cave, 
and thus possessed subtle inhibitory potency on Na+/K+-
Figure 6.  Molecular fitness of representative ginsenosides in the cave of the extracellular binding pocket of the Na+/K+-ATPase α subunit. 
Green cave of dimensional limitations for ginsenoside fitness was the same as that shown in Figure 4.  Red and brown colors show the glucose 
molecules attached to the C-6 and C-20 positions of the steroid-like structure.  Yellow balls indicate the extended dimensions of ginsenosides after 
hydroxylation (PPT) or glycosylation (Rh1, Rd, and Rb1) at the C-6 or C-20 positions.
ATPase.
Discussion
Based on experimental observation and theoretical 
modeling, we found that ginsenosides with sugar moieties at-
tached only to the C-3 position of the steroid-like structure, 
equivalent to the sugar position in cardiac glycosides, and 
possessed inhibitory potency on Na+/K+-ATPase activity. 
Sugar attachment to the C-6 or C-20 position of the steroid-
like structure presumably caused steric hindrance for the en-
trance of ginsenosides into the extracellular binding pocket 
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of the Na+/K+-ATPase α subunit, and thus significantly 
reduced or completely abolished their inhibitory potency. 
Paradoxically, most ginsenosides found in ginseng and sanqi 
have not appeared to be competent inhibitors for Na+/K+-
ATPase due to their sugar attachment to the C-6 or C-20 
position of the steroid-like structure.  Nevertheless, ginseno-
sides might act as prodrugs, as they tend to be metabolized 
to their active forms by intestinal bacterial deglycosylation 
after oral administration[8].  Commonly, the metabolites 
could be easily absorbed by the intestines due to the increase 
of hydrophobicity after deglycosylation, and might display 
the same or different pharmacological actions in comparison 
with their parent compounds[24,25].  While our experimental 
observation and theoretical modeling were executed using 
porcine Na+/K+-ATPase, the observed inhibitory potency of 
ginsenosides was presumably applicable to human Na+/K+-
ATPase, since isoforms of this enzyme in diverse species were 
highly conserved evolutionarily.  In fact, the amino acid se-
quence identity between porcine and the human α1 subunit 
of Na+/K+-ATPase was found to be up to 98%.  In view of 
the results observed in the current study and those reported 
in the available literature, we propose that the cardiac thera-
peutic effects of ginseng and sanqi should be at least partly 
attributed to the effective inhibition of Na+/K+-ATPase by 
their metabolized ginsenosides, with sugar moieties attached 
only to the C-3 position of the steroid-like structure. 
Ginsenosides are also demonstrated to be the pharmaco-
logically-active ingredients responsible for the effects of gin-
seng on the central and peripheral nervous systems[7].  They 
have been reported to possess reversible and selective inhibi-
tory effects on voltage-dependent ion channels (such as the 
Ca2+, K+, and Na+ channels) and ligand-gated ion channels 
(such as N-methyl-D-aspartate, some subtypes of nicotinic 
acetylcholine, and 5-hydroxytryptamine type 3 receptors), 
although little is known about the exact mechanisms.  As the 
inhibition of Na+/K+-ATPase also leads to the fluctuation 
of Ca2+, K+, and Na+ concentrations, it will be interesting to 
see if any cross-talks are held among these ion channels after 
being inhibited by ginsenosides, and as a result, exhibit the 
pharmacological actions of ginseng and sanqi. 
Cardiac glycosides have been demonstrated to provide 
neuroprotection against ischemic stroke in a cortical brain 
slice-based compound screening platform[26].  Neuroprotec-
tive activity and delayed therapeutic potential were observed 
for cardiac glycosides in this brain slice assay model.  Recent-
ly, we demonstrated that magnesium lithospermate B, a de-
rivative of caffeic acid tetramer, present as the major soluble 
ingredient in danshen (the dried roots of medicinal plant Sal-
via miltiorrhiza), possessed a cardiac therapeutic activity by 
its effective inhibition on Na+/K+-ATPase and exhibited the 
same neuroprotective effect against ischemic stroke in a simi-
lar brain slice assay model[27].  Similar to cardiac glycosides 
and magnesium lithospermate B, we found that ginsenosides 
possessed inhibitory potency on Na+/K+-ATPase in this 
study.  In previously published studies, similar neuroprotec-
tive effects were reported for ginsenosides against ischemic 
stroke, and some of the results were observed under the 
same brain slice assay model[28–32].  It remains to be investi-
gated whether ginsenosides, as well as cardiac glycosides and 
magnesium lithospermate B, exert neuroprotection against 
ischemic stroke via the same mechanism triggered by the in-
hibition of Na+/K+-ATPase.
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